Kato et al., 1985 - Google Patents
Mid‐Trimester Therapeutic Abortion by Vaginal Suppository of 16, 16‐Dimethyl‐Trans‐Δ2‐Prostaglandin E1Kato et al., 1985
- Document ID
- 12428324629882784386
- Author
- Kato K
- Furuya K
- Makimura N
- Nagata I
- Ishida M
- Seki K
- Publication year
- Publication venue
- Asia‐Oceania Journal of Obstetrics and Gynaecology
External Links
Snippet
A new analog of PGE1 was vaginally administered with (n= 20) or without (n= 29) laminaria tents and metreurynter to pregnant women during mid‐trimester for therapeutic abortion. All patients successfully aborted. The abortion time was short, the amount of bleeding was …
- 206010000210 Abortion 0 title abstract description 30
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. Prostaglandin E2, Prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/899—Menstrual disorder
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/931—Veneral disease
- Y10S514/934—Virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/912—Ophthalmic
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU701328B2 (en) | Water-based topical cream containing nitroglycerin; method of preparation and use thereof | |
| Bygdeman et al. | Reassessment of systemic administration of prostaglandins for induction of midtrimester abortion | |
| Trofatter Jr | Cervical ripening | |
| Goddard et al. | Genital tract pressures in mares: II. Changes induced by oxytocin and prostaglandin F2α | |
| Bygdeman | The use of prostaglandins and their analogues for abortion | |
| Karim et al. | Termination of early pregnancy (menstrual induction) with 16-phenoxy-ω-tetranor PGE2 methylsulfonylamide | |
| Cates Jr et al. | Sudden collapse and death of women obtaining abortions induced with prostaglandin F2α | |
| Behrman et al. | Prostaglandins in reproduction | |
| Takagi et al. | Termination of early pregnancy by ONO-802 suppositories (16, 16-dimethyl-trans-Δ2-PGE1 methyl ester) | |
| WILLIAMS et al. | Use of prostaglandin E2 topical gel in high-risk patients: a critical analysis | |
| Kato et al. | Mid‐Trimester Therapeutic Abortion by Vaginal Suppository of 16, 16‐Dimethyl‐Trans‐Δ2‐Prostaglandin E1 | |
| Amy et al. | Intrauterine administration of L‐Noradrenaline and propanolol during the second trimester of pregnancy | |
| JPS6193119A (en) | Synergistically effective contraceptive drug composition | |
| Corson et al. | Intra-amniotic prostaglandin F2α to induce midtrimester abortion | |
| Bygdeman | Menstrual regulation with prostaglandins | |
| DARNEY | Preparation of the cervix: hydrophilic and prostaglandin dilators | |
| Karim et al. | Cervical dilatation with 16, 16 dimethyl PGE2 p-benzaldehyde semicarbazone ester prior to vacuum aspiration in first trimester nulliparae | |
| Greer et al. | Preliminary experience with 15 (S) 15-methyl prostaglandin F2α for midtrimester abortion | |
| Braaksma et al. | Intrauterine extra-amniotic administration of prostaglandin F2α for therapeutic abortion: early myometrial effects | |
| Hill et al. | Mid‐trimester termination of pregnancy with 16, 16‐dimethyl‐trans‐Δ2 PGE1 vaginal pessaries: A comparison with intra‐and extra‐amniotic prostaglandin E2 administration | |
| Lauersen | Investigation of prostaglandins for abortion | |
| Ballard et al. | Midtrimester abortion with intramuscular injection of 15-methyl-prostaglandin E2 | |
| Leader et al. | Vaginally administered 16, 16-dimethyl-prostaglandin E2 as an agent for pre-operative cervical dilatation | |
| Filshie | Medical and surgical methods of early termination of pregnancy | |
| Shaala et al. | Cervical prostaglandin injection: a novel method of administration for ripening the cervix and induction of labor |